B-cell Malignancy
13
8
8
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
1 terminated out of 13 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (13)
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Phase I Study of HRS-1635 in B-cell Malignancies
Phase I Study of HRS-3005 in B-cell Malignancies
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
CD19-CAR-T in B-cell Malignancies Patients
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies